Development and pre-clinical aspects of pimecrolimus;Entstehungsgeschichte und präklinisches profil von pimecrolimus

Hautarzt

Volumn 54, Issue 5, 2003, Pages 405-412

  Stutz A ^a,b   Grassberger, M ^a   Meingassner, J G ^a  

^a Norvatis Forschungsinstitut   (Austria)

^b Novartis Forschungsinstitut   (Austria)

Author keywords

Ascomycin; Pharmacology; Pimecrolimus; Topical calcineurin inhibitors; Topical non steroids

Indexed keywords

ASCOMYCIN; CLOBETASOL PROPIONATE; CORTICOSTEROID; PIMECROLIMUS; TACROLIMUS;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG PENETRATION; DRUG SAFETY; HUMAN; IMMUNOPATHOLOGY; NONHUMAN; SIDE EFFECT; SKIN ATROPHY; SKIN PERMEABILITY;

EID: 0038509268     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-003-0519-0     Document Type: Article

References (21)

1. Gupta AK, Brown MD, Ellis CN et al. (1989) Cyclosporine in dermatology. J Am Acad Dermatol 21:1245-1256
2. Hermann RC, Taylor RS, Ellid CN et al. (1988) Topical cyclosporin for psoriasis: in vitro skin penetration and clinical study. Skin Pharmacol 1:246-249
3. Schmook FP, Stuetz A, Reinhardt J (1993) Skin penetration of Sandimmune (Cyclosporin A) in rat skin in vitro: effects of penetration enhancers and solvents. Skin Pharmacol 6:116-124
4. Meingassner JG, Stuetz A (1992) Immunosuppressive macrolides of the type FK506: a novel class of topical agents for treatment of skin diseases? J Invest Dermatol 98:851
5. Rappersberger K, Meingassner JG, Fialla R et al. (1996) Clearing of psoriasis by a novel immunosuppressive macrolide. J Invest Dermatol 106:701-710
6. Reitamo S, Spuls B, Sassolas B et al. (2001) Efficacy of sirolimus (rapamycin) administered concomitantly with a subtherapeutic dose of cyclosporine in the treatment of severe psoriasis: a randomized controlled trial. Br J Dermatol 145:438-445
7. Grassberger M, Baumruker T, Enz A et al. (1999) A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology. Br J Dermatol 141:264-273
8. Winiski A, Wang S, Schwendinger H, Stuetz A (2002) Inhibitory activity of pimecrolimus and tacrolimus on induced cytokine mRNA and protein expression in a human T cell line (Jurkat) measured via RT PCR and ELISA (conference abstract). J Invest Dermatol 119:347
9. Kalthoff FS, Chung J, Stuetz A (2002) Pimecrolimus inhibits upregulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells. Clin Exp Immunol 130:85-92
10. Hultsch T, Müller KD, Meingassner JG et al. (1998) Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner. Arch Derm Res 290:501-507
11. Zuberbier T, Chong SU, Grunow K et al. (2001. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 108:275-280
12. Kalthoff FS, Chung J, Musser P, Stuetz A (2002) Pimecrolimus does not affect the expression of surface markers and functions of dendritic cells, in contrast to corticosteroids (conference abstract). J Invest Dermatol 119:311
13. Meingassner JG, Kowalsky E, Schwendinger H, Stuetz A (2002) Pimecrolimus (SDZ ASM 981) does not affect Langerhans' cells in murine epidermis, in contrast to corticosteroids (conference abstract). J Invest Dermatol, 119:347
14. Stuetz A, Grassberger M, Meingassner JG (2001) Pimecrolimus (Elidel®, SDZ ASM 981) - preclinical pharmacological profile and skin selectivity. Sem Cutan Med Surg 20:233-241
15. Billich A, Aschauer H, Stuetz A (2002) permeates less through skin than corticosteroids and tacrolimus (conference abstract). J Invest Dermatol 119:346
16. Meingassner J, Grassberger M, Fahrngruber H et al. (1997) A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: in vivo pharmacology. Br J Dermatol 137:568-576
17. Queille-Roussel C, Paul C, Duteil L et al. (2001) The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for four weeks: a randomised, double-blind controlled study. Br J Dermatol 144:507-13
18. Meingassner JG, Fahrngruber H, Schweitzer A et al. (2002) Pimecrolimus inhibits allergic contact dermatitis in rodents without affecting draining lymph nodes, different to tacrolimus (conference abstract). J Invest Dermatol 119:343
19. Neckermann G, Bavandi A, Meingassner JG (2000) Atopic dermatitis-like symptoms in hypomagnesaemic hairless rats are prevented and inhibited by systemic or topical SDZ ASM 981. Br J Dermatol 142:669-679
20. Rappersberger K, Komar M, Ebelin ME et al. (2002) Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 119:876-888
21. Meingassner JG, Stuetz A (1992) Antiinflammatory effects of macrophilin-interacting drugs in animal models of irritant and allergic contact dermatitis. Int Arch Allergy Immunol 99:486-489